close
Pharma and Biotech
Menu
close
Pharma and Biotech
close
Pharma and Biotech
Menu
close
Pharma and Biotech
Pharma and Biotech
Menu
close
Cell and gene therapies are among the products that require particular care during manufacturing. Even minor deviations in the process can affect the safety, efficacy, or available quantity of the drug. For manufacturers, this means that every step of the filling process must be precise. Fill and finish processes must protect sensitive products and prevent losses, while remaining flexible enough to meet clinical and regulatory requirements.
Gene therapies pose specific challenges for filling processes. Available quantities are often limited, and manufacturing processes must remain consistent throughout the entire batch. Many manufacturers now process clinical batches in-house, which further increases the demand for safe and seamless filling.
A key consideration is the handling of the containers. CZ vials are widely used in this context because they provide good protection for sensitive molecules. At the same time, they are sensitive to mechanical stress and must therefore be transported and handled with particular care. In addition, there are further requirements for isolators and coordinated pressure cascades, which ensure a controlled and safe process.
Regulatory requirements are also becoming stricter. Precise dosing, comprehensive monitoring, and reliable traceability are now essential. Systems that lack sufficient flexibility or fail to provide end-to-end process control quickly reach their limits. It is therefore becoming increasingly important for manufacturers to rely on solutions that can handle different formats, minimize manual intervention, and ensure high accuracy.
To meet the specific requirements of gene therapies, manufacturers need filling technologies that are both precise and gentle. Modern systems combine several functions that work together to enable a stable and well-controlled process. Precise dosing is a key element. Peristaltic pumps and continuous weight monitoring ensure that each vial is filled with exact precision. If the system detects a deviation, it can automatically add more product, thereby preventing vials from being rejected due to underfilling. This increases the usable product volume and improves yield, particularly for valuable AAV-based therapies.
Another key focus is on the safe handling of the containers used. Particularly with CZ vials, which are being used more and more frequently, gentle, robot-assisted handling ensures that the containers are guided reliably through the process without being subjected to stress.
For many operators, flexibility is also a key factor. Systems that can switch between different vial formats without the need for tools simplify operations in clinical settings and provide investment security as requirements change. Supported by integrated monitoring, a common HMI, and SCADA structures, such processes can be controlled safely and efficiently.
The OPTIMA FillCell combines the core functions required for filling valuable cell and gene therapies. Technologies that minimize product loss and precise dosing ensure high yield, while robot-assisted, gentle handling preserves the integrity of sensitive CZ vials. For BSL-2 applications, an integrated isolator and continuous pressure cascades are available to create a controlled and safe environment. Complemented by a shared HMI and SCADA system as well as tool-free format changes, the system offers a highly flexible and easy-to-manage solution for a variety of production requirements.
